Spero-Smith Investment Advisers’s Novartis NVS Stock Holding History

Spero-Smith Investment Advisers’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$1.7M	Sell	23,974 -279	-1%	-$20.3K	2.28%	19
2016 Q2	$1.79M	Buy	24,253 +140	+0.6%	+$9.67K	2.23%	20
2016 Q1	$1.56M	Buy	24,113 +44	+0.2%	+$2.99K	1.96%	23
2015 Q4	$1.86M	Sell	24,069 -664	-3%	-$52.7K	2.36%	19
2015 Q3	$2.04M	Sell	24,733 -8,561	-26%	-$762K	2.76%	14
2015 Q2	$2.93M	Sell	33,294 -223	-0.7%	-$20.5K	3.34%	6
2015 Q1	$2.96M	Sell	33,517 -417	-1%	-$37K	3.29%	5
2014 Q4	$2.82M	Buy	33,934 +50	+0.1%	+$4.14K	3.2%	8
2014 Q3	$2.86M	Sell	33,884 -597	-2%	-$48.3K	3.32%	7
2014 Q2	$2.8M	Sell	34,481 -703	-2%	-$55.3K	3.16%	8
2014 Q1	$2.68M	Sell	35,184 -218	-0.6%	-$15.9K	3.17%	8
2013 Q4	$2.55M	Sell	35,402 -1,492	-4%	-$104K	2.92%	11
2013 Q3	$2.54M	Sell	36,894 -1,830	-5%	-$121K	3.15%	10
2013 Q2	$2.45M	Buy	+38,724	New	+$2.52M	3.05%	7

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Spero-Smith Investment Advisers's NVS Position: Q3 2016 in Review

Spero-Smith Investment Advisers reduced its Novartis (NVS) stake by 1.2% in Q3 2016, selling an estimated $20.3K and leaving 23,974 shares worth $1.7M. The position accounts for 2.28% of the portfolio, ranked #19.

Spero-Smith Investment Advisers first reported a position in NVS in Q2 2013 and has held it in 14 quarters since. The position peaked at $2.96M in Q1 2015. 878 funds tracked by Wall St. Rank hold NVS as of Q3 2016.

Spero-Smith Investment Advisers held 23,974 shares of Novartis worth $1.7M as of Q3 2016.
Spero-Smith Investment Advisers sold 279 Novartis shares in Q3 2016, an estimated $20.3K.
Novartis made up 2.28% of Spero-Smith Investment Advisers's portfolio in Q3 2016, its #19 holding.
Spero-Smith Investment Advisers first reported a position in Novartis in Q2 2013 and has held it in 14 quarters since.
Spero-Smith Investment Advisers's Novartis position peaked at $2.96M in Q1 2015.
878 funds tracked by Wall St. Rank held Novartis as of Q3 2016.

Based on Spero-Smith Investment Advisers's 13F filing for Q3 2016, filed 31 Oct 2016.